Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy

Heart

Volumn 91, Issue 7, 2005, Pages 926-931

  Vanderheyden, Marc ^a   Paulus, W J ^a   Voss, M ^b   Knuefermann, P ^c   Sivasubramanian, N ^c   Mann, D ^c   Baumgarten, G ^d  

^a CARDIOVASCULAR CENTER   (Belgium)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN TISSUE; IL 1BETA GENE; IL 6 GENE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TNFALPHA GENE;

AGED; AORTIC VALVE STENOSIS; CARDIAC OUTPUT, LOW; CARDIOMYOPATHY, DILATED; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEMODYNAMIC PROCESSES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIUM; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 21044455451     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.035733     Document Type: Article

References (36)

1. Wong F, Seta Y, Baumgarten G, et al. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 2001;103:1296-302.
2. Shioi T, Matsumori A, Furukawa Y, et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 1997;81:664-71.
3. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1844-50.
4. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
5. Levine B, Kolman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
6. Yokoyama T, Vaca L, Rossen RD, et al. Cellular bosis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
7. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
8. Birks EJ, Latif N, Owen V, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001;104(12 suppl 1):I233-40.
9. Arstall MA, Sawyer DB, Fukazawa R, et al. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res 1999;85:829-40.
10. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42.
11. Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426-30.
12. Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 2001;3:415-21.
13. Kapadia SR, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95.
14. Baumgarten G, Knuefermann P, Lalra D, et al. Load-dependent and - independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 2002;105:2192-7.
15. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 1999;100:1189-93.
16. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
17. Torre-Amione G, MacLellan W, Kapodia S, et al. Tumor necrosis factor-alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transplant Proc 1998;30:875-7.
18. Clark AL, Loebe M, Potapav EV, et al. Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J 2001;22:2275-83.
19. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
20. Heymes C, Vanderheyden M, Bronzwaer JG, et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999;99:3009-16.
21. Hatle L, Angelsen BA, Tromsdal A. Non-invasive assessment of aortic stenosis by Doppler ultrasound. Br Heart J 1980;43:284-92.
22. Douglas PS, Reichek N. Estimation of wall stress and left ventricular mass by noninvasive techniques and clinical implications. Cardiovasc Clin 1986;17:103-28.
23. Serneri GGN, Modesti PA, Boddi M, et al. Cardiac growth factors in human hypertrophy: relations with myocardial contractility and wall stress. Circ Res 1999;85:57-67.
24. Vonderheyden M, Van Meerbeeck, Van Bouwel E, et al. A rare case of inflammatory pseudotumour of the bronchus, occurring in an achondroplastic woman. Eur Respir J 1994;7:826-8.
25. Francis SE, Holden H, Holt CM, et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopalhy. J Mol Cell Cardiol 1998;30:215-23.
26. Habib FM, Springall DR, Davies GJ, et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopothy. Lancet 1996;347:1151-5.
27. Birks EJ, Burton PB, Owen V, et al. Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 2000;102(19 suppl III):III352-8.
28. Kapadia SR, Yakoob K, Nader S, et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000;36:208-12.
29. Blaxoll BC, Tschannen-Moran BM, Milano CA, et al. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003;41:1096-106.
30. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-94.
31. Munger MA, Johnson B, Amber IJ, et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopothic dilated cardiomyopothy. Am J Cardiol 1996;77:723-7.
32. Petretta M, Condorelli GL, Spinelli L, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J 2000;140:E28.
33. Tsutamota T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8.
34. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001;104:826-31.
35. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-81.
36. Satah M, Nakamura M, Saitoh H, et al. Tumor necrosis fodor-alpha- converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation 1999;99:3260-5.